{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:49:00Z","timestamp":1791431340547,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37AG026160"],"award-info":[{"award-number":["R37AG026160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL139065"],"award-info":[{"award-number":["R01HL139065"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM044757"],"award-info":[{"award-number":["R01GM044757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R15NS116511"],"award-info":[{"award-number":["R15NS116511"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61NS111075"],"award-info":[{"award-number":["R61NS111075"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM027906"],"award-info":[{"award-number":["GM027906"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jbc.2023.102956","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T22:12:37Z","timestamp":1675116757000},"page":"102956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Early-phase drug discovery of \u03b2-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5"],"prefix":"10.1016","volume":"299","author":[{"given":"Piyali","family":"Guhathakurta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-2286","authenticated-orcid":false,"given":"Robyn T.","family":"Rebbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Denha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Atang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam W.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2023.102956_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0169-328X(98)00068-0","article-title":"Characterization of a new beta-spectrin gene which is predominantly expressed in brain","volume":"57","author":"Ohara","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.jbc.2023.102956_bib2","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1073\/pnas.1001522107","article-title":"Targeted deletion of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes","volume":"107","author":"Stankewich","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2023.102956_bib3","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1093\/hmg\/ddq279","article-title":"Beta-III spectrin mutation L253P associated with spinocerebellar ataxia type 5 interferes with binding to Arp1 and protein trafficking from the Golgi","volume":"19","author":"Clarkson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2023.102956_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng1728","article-title":"Spectrin mutations cause spinocerebellar ataxia type 5","volume":"38","author":"Ikeda","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jbc.2023.102956_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/srep21375","article-title":"A\u00a0human beta-III-spectrin spinocerebellar ataxia type 5 mutation causes high-affinity F-actin binding","volume":"6","author":"Avery","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2023.102956_bib6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41467-017-01367-w","article-title":"Structural basis for high-affinity actin binding revealed by a beta-III-spectrin SCA5 missense mutation","volume":"8","author":"Avery","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2023.102956_bib7","doi-asserted-by":"crossref","first-page":"dev194530","DOI":"10.1242\/dev.194530","article-title":"betaIII spectrin controls the planarity of Purkinje cell dendrites by modulating perpendicular axon-dendrite interactions","volume":"147","author":"Fujishima","year":"2020","journal-title":"Development"},{"key":"10.1016\/j.jbc.2023.102956_bib8","doi-asserted-by":"crossref","first-page":"E9376","DOI":"10.1073\/pnas.1707108114","article-title":"beta-III-spectrin spinocerebellar ataxia type 5 mutation reveals a dominant cytoskeletal mechanism that underlies dendritic arborization","volume":"114","author":"Avery","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2023.102956_bib9","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1523\/JNEUROSCI.0876-14.2014","article-title":"Mutant beta-III spectrin causes mGluR1alpha mislocalization and functional deficits in a mouse model of spinocerebellar ataxia type 5","volume":"34","author":"Armbrust","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2023.102956_bib10","doi-asserted-by":"crossref","first-page":"16581","DOI":"10.1523\/JNEUROSCI.3332-11.2011","article-title":"beta-III spectrin is critical for development of purkinje cell dendritic tree and spine morphogenesis","volume":"31","author":"Gao","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2023.102956_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/cge.13562","article-title":"Heterozygous missense variants of SPTBN2 are a frequent cause of congenital cerebellar ataxia","volume":"96","author":"Nicita","year":"2019","journal-title":"Clin. Genet."},{"key":"10.1016\/j.jbc.2023.102956_bib12","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.015417","article-title":"Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting beta-III-spectrin","volume":"296","author":"Rebbeck","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2023.102956_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A\u00a0Simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.jbc.2023.102956_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/bios8040099","article-title":"Red-shifted FRET biosensors for high-throughput fluorescence lifetime screening","volume":"8","author":"Schaaf","year":"2018","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.jbc.2023.102956_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1087057116680151","article-title":"High-throughput spectral and lifetime-based FRET screening in living cells to identify small-molecule effectors of SERCA","volume":"22","author":"Schaaf","year":"2017","journal-title":"SLAS Discov."},{"key":"10.1016\/j.jbc.2023.102956_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29685-z","article-title":"Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells","volume":"8","author":"Stroik","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2023.102956_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1087057113510740","article-title":"Discovery of enzyme modulators via high-throughput time-resolved FRET in living cells","volume":"19","author":"Gruber","year":"2014","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.jbc.2023.102956_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1087057116674312","article-title":"High-throughput screens to discover small-molecule modulators of ryanodine receptor calcium release channels","volume":"22","author":"Rebbeck","year":"2017","journal-title":"SLAS Discov."},{"key":"10.1016\/j.jbc.2023.102956_bib19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/s41598-020-58461-1","article-title":"RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca(2+) assays","volume":"10","author":"Rebbeck","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2023.102956_bib20","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1074\/jbc.RA118.002702","article-title":"High-throughput screen, using time-resolved FRET, yields actin-binding compounds that modulate actin-myosin structure and function","volume":"293","author":"Guhathakurta","year":"2018","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2023.102956_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100840","article-title":"Cardiac myosin-binding protein C interaction with actin is inhibited by compounds identified in a high-throughput fluorescence lifetime screen","volume":"297","author":"Bunch","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2023.102956_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aav5637","article-title":"Noncompetitive inhibitors of TNFR1 probe conformational activation states","volume":"12","author":"Lo","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jbc.2023.102956_bib23","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1177\/2472555217706478","article-title":"An innovative high-throughput screening approach for discovery of small molecules that inhibit TNF receptors","volume":"22","author":"Lo","year":"2017","journal-title":"SLAS Discov."},{"key":"10.1016\/j.jbc.2023.102956_bib24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jalz.2019.06.4954","article-title":"Targeting the ensemble of heterogeneous tau oligomers in cells: a novel small molecule screening platform for tauopathies","volume":"15","author":"Lo","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jbc.2023.102956_bib25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1087057116679637","article-title":"Spectral unmixing plate reader: high-throughput, high-precision FRET assays in living cells","volume":"22","author":"Schaaf","year":"2017","journal-title":"SLAS Discov."},{"key":"10.1016\/j.jbc.2023.102956_bib26","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbc.2023.102956_bib27","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1021\/acs.jmedchem.5b01105","article-title":"An aggregation advisor for ligand discovery","volume":"58","author":"Irwin","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2023.102956_bib28","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1681\/ASN.2005070706","article-title":"Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis","volume":"16","author":"Weins","year":"2005","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.jbc.2023.102956_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ajhg.2011.04.021","article-title":"Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy","volume":"88","author":"Duff","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.jbc.2023.102956_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jbc.2023.102956_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10408347.2020.1726726","article-title":"Biological properties and analytical methods for micafungin: a critical review","volume":"51","author":"Marena","year":"2021","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.jbc.2023.102956_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jbc.2023.102956_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.brainresbull.2016.04.002","article-title":"Ginsenoside Rb1 as a neuroprotective agent: a review","volume":"125","author":"Ahmed","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jbc.2023.102956_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2017.12.012","article-title":"Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease","volume":"131","author":"Zhang","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jbc.2023.102956_bib35","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1523\/JNEUROSCI.6065-09.2010","article-title":"Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans","volume":"30","author":"Perkins","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.jbc.2023.102956_bib36","first-page":"4448","article-title":"Posterior cerebellar Purkinje cells in an SCA5\/SPARCA1 mouse model are especially vulnerable to the synergistic effect of loss of beta-III spectrin and GLAST","volume":"25","author":"Perkins","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jbc.2023.102956_bib37","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41598-022-05762-2","article-title":"beta-III-spectrin N-terminus is required for high-affinity actin binding and SCA5 neurotoxicity","volume":"12","author":"Denha","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2023.102956_bib38","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1073\/pnas.1420101112","article-title":"Amplitude of the actomyosin power stroke depends strongly on the isoform of the myosin essential light chain","volume":"112","author":"Guhathakurta","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.jbc.2023.102956_bib39","doi-asserted-by":"crossref","first-page":"103101","DOI":"10.1063\/1.3480647","article-title":"High -performance time-resolved fluorescence by direct waveform recording","volume":"81","author":"Muretta","year":"2010","journal-title":"Rev. Sci. Instrum"},{"key":"10.1016\/j.jbc.2023.102956_bib40","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/cells9051170","article-title":"Live-cell cardiac-specific high-throughput screening platform for drug-like molecules that enhance Ca(2+) transport","volume":"9","author":"Schaaf","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jbc.2023.102956_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"Vmd: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J.\u00a0Mol. Graph"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925823000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925823000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:54:45Z","timestamp":1777409685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925823000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0021925823000881"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2023.102956","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early-phase drug discovery of \u03b2-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2023.102956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"102956"}}